{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:30:12Z","timestamp":1784143812962,"version":"3.55.0"},"reference-count":160,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022928","name":"Shiv Nadar Foundation","doi-asserted-by":"publisher","award":["BMI\/EZH2"],"award-info":[{"award-number":["BMI\/EZH2"]}],"id":[{"id":"10.13039\/100022928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022928","name":"Shiv Nadar Foundation","doi-asserted-by":"publisher","award":["SGI-110"],"award-info":[{"award-number":["SGI-110"]}],"id":[{"id":"10.13039\/100022928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010577","name":"Toyota Motor Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001428","name":"Amity University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013934","name":"Bundesministerium des Innern, f\u00fcr Bau und Heimat","doi-asserted-by":"publisher","award":["G9a\/EHMT2"],"award-info":[{"award-number":["G9a\/EHMT2"]}],"id":[{"id":"10.13039\/501100013934","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bbcan.2025.189261","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T17:31:03Z","timestamp":1736443863000},"page":"189261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combating chemoresistance: Current approaches & nanocarrier mediated targeted delivery"],"prefix":"10.1016","volume":"1880","author":[{"given":"Siuli","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata Kumar","family":"Pore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Kumeria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranu","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.bbcan.2025.189261_bb0005","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.7150\/thno.29098","article-title":"Chemoresistance of cancer cells: requirements of tumor microenvironment-mimicking in vitro models in anti-cancer drug development","volume":"8","author":"Jo","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2025.189261_bb0010","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms19061690","article-title":"Pharmacological targeting of cell cycle, apoptotic and cell adhesion signaling pathways implicated in chemoresistance of cancer cells","volume":"19","author":"Alimbetov","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4097\/kja.21327","article-title":"Effect of chemotherapy on effect-site concentration of propofol for loss of consciousness in patients with colorectal cancer","volume":"75","author":"Ki","year":"2021","journal-title":"Korean J. Anesthesiol."},{"key":"10.1016\/j.bbcan.2025.189261_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","article-title":"Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review","volume":"15","author":"Hossen","year":"2019","journal-title":"J. Adv. Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4103\/apjon.apjon_19_19","article-title":"Improving information provision on chemotherapy-induced alopecia and scalp cooling: a comprehensive approach including a website and web-based decision tool","volume":"6","author":"Van Den Hurk","year":"2019","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"10.1016\/j.bbcan.2025.189261_bb0030","series-title":"Scalp Cooling Successfully Prevents Alopecia in Breast cancer Patients Undergoing Anthracycline\/Taxane-Based Chemotherapy","author":"Vasconcelos","year":"2018"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189261_bb0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","article-title":"Mechanism and medical implications of mammalian autophagy","volume":"19","author":"Dikic","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/15548627.2017.1378838","article-title":"Autophagy pathway: cellular and molecular mechanisms","volume":"14","author":"Yu","year":"2017","journal-title":"Autophagy [Internet]"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189261_bb0045","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1007\/s00018-021-03988-3","article-title":"The lysosome as an imperative regulator of autophagy and cell death","volume":"78","author":"Mahapatra","year":"2021","journal-title":"Cell Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph14010060","article-title":"Cancer stem cells and nucleolin as drivers of carcinogenesis","volume":"14","author":"Carvalho","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0055","first-page":"32","article-title":"Cancer therapeutics strategy using nano-carrier mediated natural drugs","volume":"114","author":"Shaw","year":"2022","journal-title":"J. Achiev. Mater. Manuf. Eng."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189261_bb0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.10226","article-title":"Cancer chemoresistance: the relationship between p53 and multidrug transporters","volume":"98","author":"Bush","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189261_bb0075","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.drudis.2020.11.032","article-title":"Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance","volume":"26","author":"Shih","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"35","key":"10.1016\/j.bbcan.2025.189261_bb0080","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"issue":"32","key":"10.1016\/j.bbcan.2025.189261_bb0085","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.18410","article-title":"Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells","volume":"8","author":"Han","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189261_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0095","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3892\/ijo.2015.2898","article-title":"Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3","volume":"46","author":"Tang","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3892\/or.2016.5259","article-title":"MiR-20b reduces 5-FU resistance by suppressing the ADAM9\/EGFR signaling pathway in colon cancer","volume":"37","author":"Fu","year":"2017","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3892\/or.2021.7978","article-title":"Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines","volume":"45","author":"Suetsugu","year":"2021","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040739","article-title":"Re-discovery of pyrimidine salvage as target in cancer therapy","volume":"11","author":"Walter","year":"2022","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189261_bb0115","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/cas.14532","article-title":"5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes","volume":"111","author":"Blondy","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2025.189261_bb0120","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/antiox10050701","article-title":"Glutathione S-transferases in cancer","volume":"10","author":"Singh","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bbcan.2025.189261_bb0125","doi-asserted-by":"crossref","first-page":"738222","DOI":"10.3389\/fonc.2021.738222","article-title":"Evaluating the risk of breast cancer recurrence and metastasis after adjuvant tamoxifen therapy by integrating polymorphisms in cytochrome P450 genes and clinicopathological characteristics","volume":"11","author":"Pang","year":"2021","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189261_bb0130","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/17425255.2020.1815705","article-title":"Role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity","volume":"16","author":"Tao","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189261_bb0135","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/jca.13141","article-title":"Cancer hallmarks, biomarkers and breast cancer molecular subtypes","volume":"7","author":"Dai","year":"2016","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0145","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell [Internet]"},{"key":"10.1016\/j.bbcan.2025.189261_bb0150","series-title":"Breast Cancer Prevention View Project Next Generation Leukemia Diagnostics and Therapy Through p53 Isoform Analysis View Project","author":"Knappskog","year":"2012"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189261_bb0155","article-title":"Hypoxia and selective autophagy in cancer development and therapy","volume":"10","author":"Daskalaki","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2025.189261_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-023-01346-3","article-title":"Autophagy-modulating biomaterials: multifunctional weapons to promote tissue regeneration","volume":"22","author":"Wu","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","article-title":"HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1","volume":"370","author":"Bamodu","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0170","first-page":"46","article-title":"microRNA targeted to chronic myeloid leukemia Bcr-Abl oncogene screen using deacetylase inhibitor","volume":"98","author":"Ai","year":"2018","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/1878-0261.13535","article-title":"Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria-related pathways in colorectal cancer","volume":"18","author":"Everest-Dass","year":"2024","journal-title":"Mol. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0180","first-page":"1","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transd. Target. Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0185","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0190","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s11033-020-06094-y","article-title":"Alternative splicing modulates cancer aggressiveness: role in EMT\/metastasis and chemoresistance","volume":"48","author":"Roy Burman","year":"2021","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0195","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.stemcr.2019.08.015","article-title":"ALDH-dependent glycolytic activation mediates stemness and paclitaxel resistance in patient-derived spheroid models of uterine endometrial cancer","volume":"13","author":"Mori","year":"2019","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189261_bb0200","article-title":"Ajuba overexpression promotes breast cancer chemoresistance and glucose uptake through TAZ-GLUT3\/survivin pathway","volume":"1","author":"Li","year":"2022","journal-title":"Biomed. Res. Int."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189261_bb0205","doi-asserted-by":"crossref","first-page":"15941","DOI":"10.1002\/jcp.28253","article-title":"Wnt1-inducible signaling protein 1 regulates laryngeal squamous cell carcinoma glycolysis and chemoresistance via the YAP1\/TEAD1\/GLUT1 pathway","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188457","article-title":"Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer","volume":"1874","author":"Tilekar","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189261_bb0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2020.09.012","article-title":"Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated Warburg effect","volume":"495","author":"Shi","year":"2020","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0220","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3892\/mmr.2014.2271","article-title":"Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II","volume":"10","author":"Jiang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbcan.2025.189261_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/PAP.0b013e3181c66f4e","article-title":"Oncogene-induced cellular senescence","volume":"17","author":"Chandeck","year":"2010","journal-title":"Adv. Anat. Pathol."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189261_bb0235","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.7150\/thno.43811","article-title":"Aurora-a\/SOX8\/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells","volume":"10","author":"Sun","year":"2020","journal-title":"Theranostics"},{"issue":"41","key":"10.1016\/j.bbcan.2025.189261_bb0240","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/onc.2016.75","article-title":"NF-\u03baB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer","volume":"35","author":"\u00d6ze\u015f","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0250","first-page":"297","article-title":"Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer","volume":"2","author":"Ponnusamy","year":"2019","journal-title":"Cancer Drug Resist."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2025.189261_bb0255","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mrrev.2008.02.004","article-title":"Epigenetic interplay between histone modifications and DNA methylation in gene silencing","volume":"659","author":"Vaissi\u00e8re","year":"2008","journal-title":"Rev. Mutat. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189261_bb0260","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1158\/0008-5472.CAN-18-1559","article-title":"Cis-acting circ-CTNNB1 promotes \u03b2-catenin signaling and Cancer progression via DDX3-mediated transactivation of YY1","volume":"79","author":"Yang","year":"2019","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0265","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2019.01.025","article-title":"Widespread and functional RNA circularization in localized prostate cancer","volume":"176","author":"Chen","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0270","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-014-0090-4","article-title":"Functions of lncRNA HOTAIR in lung cancer","volume":"7","author":"Loewen","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0275","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijbs.18834","article-title":"Targeting HSP90-HDAC6 regulating network implicates precision treatment of breast cancer","volume":"13","author":"Yu","year":"2017","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0280","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-016-0765-5","article-title":"HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells","volume":"33","author":"Wang","year":"2016","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0300","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s12276-020-0428-7","article-title":"Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms","volume":"52","author":"Jia","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0285","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master transcription factors and mediator establish super-enhancers at key cell identity genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0290","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s12276-020-0428-7","article-title":"Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms","volume":"52","author":"Jia","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0295","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1101\/gr.184986.114","article-title":"Spatial enhancer clustering and regulation of enhancer-proximal genes by cohesin","volume":"25","author":"Ing-Simmons","year":"2015","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0305","first-page":"1","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transd. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189261_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/0008-5472.CAN-17-2291","article-title":"New perspectives, opportunities, and challenges in exploring the human protein kinome","volume":"78","author":"Wilson","year":"2018","journal-title":"Cancer Res."},{"issue":"Suppl. 3","key":"10.1016\/j.bbcan.2025.189261_bb0325","doi-asserted-by":"crossref","first-page":"iii42","DOI":"10.1093\/annonc\/mdw305","article-title":"Crizotinib resistance: implications for therapeutic strategies","volume":"27","author":"Dagogo-Jack","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0335","first-page":"94","article-title":"Alectinib and brigatinib: new second-generation ALK inhibitors for the treatment of non\u2013small cell lung cancer","volume":"9","author":"Beardslee","year":"2018","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.bbcan.2025.189261_bb0405","series-title":"FDA Approval of Lymphoma Medicine Ukoniq (Umbralisib) is Withdrawn Due to Safety Concerns","author":"FDA","year":"2022"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189261_bb0410","doi-asserted-by":"crossref","first-page":"733","DOI":"10.7150\/jca.37776","article-title":"The nucleolin antagonist N6L inhibits LINE1 retrotransposon activity in non-small cell lung carcinoma cells","volume":"11","author":"Ramos","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189261_bb0340","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0345","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12288-024-01769-z","article-title":"A retrospective analysis of BCR-ABL-1 kinase domain mutations in frontline TKI resistant chronic myeloid leukemia patients: a single Centre experience","volume":"40","author":"Datta","year":"2024","journal-title":"Indian J. Hematol. Blood Transf."},{"key":"10.1016\/j.bbcan.2025.189261_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0355","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CMR.0000000000000678","article-title":"Loss of skeletal muscle area and fat-free mass during dabrafenib\/trametinib and vemurafenib\/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma","volume":"30","author":"Sengul Samanci","year":"2020","journal-title":"Melanoma Res."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189261_bb0360","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/biomedicines12071489","article-title":"Personalizing therapy outcomes through mitogen-activated protein kinase pathway inhibition in non-small cell lung cancer","volume":"12","author":"Alsharoh","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189261_bb0365","doi-asserted-by":"crossref","DOI":"10.21037\/apm-22-1432","article-title":"Melanoma\u2014the therapeutic considerations in the clinical practice","volume":"12","author":"Adeleke","year":"2023","journal-title":"Ann. Palliat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2025.189261_bb0375","first-page":"S23","article-title":"EGFR first- and second-generation TKIs\u2014there is still place for them in EGFR -mutant NSCLC patients","volume":"8","author":"Karachaliou","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189261_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103454","article-title":"Hype or hope \u2013 can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced\/metastatic NSCLC?","volume":"166","author":"Papini","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189261_bb0385","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1158\/2767-9764.CRC-22-0169","article-title":"A phase II study investigating Cabozantinib in patients with refractory metastatic colorectal cancer (AGICC 17CRC01)","volume":"2","author":"Scott","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189261_bb0390","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2025.189261_bb0415","first-page":"3408","article-title":"The mechanism of Warburg effect-induced Chemoresistance in Cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189261_bb0430","first-page":"423","article-title":"Effect of the hedgehog-inhibitor cyclopamine on mice with osteosarcoma pulmonary metastases","volume":"29","author":"Warzecha","year":"2012","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0420","first-page":"19","article-title":"Natural products to prevent drug resistance in cancer chemotherapy: a review Tanshinones and diethyl blechnics with anti-inflammatory and anti-cancer activities from salvia miltiorrhiza Bunge (Danshen), View Project","volume":"1401","author":"Yuan","year":"2017","journal-title":"Pharmacol"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189261_bb0425","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1039\/C6MB00187D","article-title":"Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer","volume":"12","author":"Mohana","year":"2016","journal-title":"Mol. BioSyst."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0435","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00280-017-3355-0","article-title":"Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells","volume":"80","author":"Xu","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0440","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3892\/ol.2015.3913","article-title":"Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy","volume":"11","author":"Huang","year":"2016","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189261_bb0445","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1158\/1535-7163.MCT-16-0763","article-title":"Metformin synergizes with BCL-XL\/BCL-2 inhibitor ABT-263 to induce apoptosis specifically in p53-defective cancer cells","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0450","first-page":"69","article-title":"Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer","volume":"4","author":"Rajendran","year":"2021","journal-title":"Cancer Drug Resist."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0455","article-title":"Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2022.5375","article-title":"Curcumin inhibits the cancer-associated fibroblast-derived chemoresistance of gastric cancer through the suppression of the JAK\/STAT3 signaling pathway","volume":"61","author":"Ham","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189261_bb0470","first-page":"2045","article-title":"Fisetin, a dietary bioflavonoid, reverses acquired cisplatin-resistance of lung adenocarcinoma cells through MAPK\/Survivin\/caspase pathway","volume":"7","author":"Zhuo","year":"2015","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0475","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/cancers13020188","article-title":"Resveratrol\u2019s anti-cancer effects through the modulation of tumor glucose metabolism","volume":"13","author":"Brockmueller","year":"2021","journal-title":"Cancers"},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2025.189261_bb0480","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11010-016-2721-2","article-title":"Regulation of nucleolin expression by miR-194, miR-206, and HuR","volume":"417","author":"Bose","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbcan.2025.189261_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jprot.2018.04.025","article-title":"Identification and validation nucleolin as a target of curcumol in nasopharyngeal carcinoma cells","volume":"182","author":"Wang","year":"2018","journal-title":"J. Proteome"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0490","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35088-x","article-title":"The anti-tumor diterpene oridonin is a direct inhibitor of Nucleolin in cancer cells","volume":"8","author":"Vasaturo","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189261_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2024.2326668","article-title":"Molecular interaction of quercetin and its derivatives against nucleolin in breast cancer: in-silico and in-vitro study","author":"Shaw","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbcan.2025.189261_bb0505","doi-asserted-by":"crossref","unstructured":"Vasaturo M, Cotugno R, Fiengo L, Vinegoni C, Dal Piaz F, De Tommasi N. The anti-tumor diterpene oridonin is a direct inhibitor of Nucleolin in cancer cells. Sci. Rep. 2018 8(1):1\u201313.","DOI":"10.1038\/s41598-018-35088-x"},{"issue":"182","key":"10.1016\/j.bbcan.2025.189261_bb0510","first-page":"1","article-title":"Identification and validation nucleolin as a target of curcumol in nasopharyngeal carcinoma cells","volume":"30","author":"Wang","year":"2018","journal-title":"J. Proteome"},{"issue":"6483","key":"10.1016\/j.bbcan.2025.189261_bb0515","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189261_bb0520","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.3390\/cancers13143540","article-title":"Trastuzumab mechanism of action; 20 years of research to unravel a dilemma","volume":"13","author":"Maadi","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189261_bb0525","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.drudis.2020.06.003","article-title":"Phytonanomedicine: a novel avenue to treat recurrent cancer by targeting cancer stem cells","volume":"25","author":"Mohapatra","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbcan.2025.189261_bb0530","series-title":"Handbook of Oncobiology: From Basic to Clinical Sciences","first-page":"1","article-title":"Combating cancer using nanomaterials: development and challenges","author":"Husain","year":"2023"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189261_bb0535","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.drudis.2020.12.016","article-title":"Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance","volume":"26","author":"Khot","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0540","doi-asserted-by":"crossref","first-page":"227","DOI":"10.15283\/ijsc19006","article-title":"Application of nanotechnology in targeting of cancer stem cells: a review","volume":"12","author":"Asghari","year":"2019","journal-title":"Int. J. Stem Cells"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189261_bb0545","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1021\/acsanm.2c01118","article-title":"Carbon nanotubes in tumor-targeted chemotherapeutic formulations: a review of opportunities and challenges","volume":"5","author":"Contreras-Torres","year":"2022","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.bbcan.2025.189261_bb0550","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.2147\/IJN.S469110","article-title":"Advances in nanotherapy for targeting senescent cells","volume":"19","author":"Shi","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0555","doi-asserted-by":"crossref","DOI":"10.1515\/ntrev-2023-0211","article-title":"Cellular senescence and nanoparticle-based therapies: current developments and perspectives","volume":"13","author":"Henschke","year":"2024","journal-title":"Nanotechnol. Rev."},{"key":"10.1016\/j.bbcan.2025.189261_bb0560","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189261_bb0565","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/0008-5472.CAN-14-3485","article-title":"Silencing \u03b23 integrin by targeted ECO\/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer","volume":"75","author":"Parvani","year":"2015","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189261_bb0570","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1039\/D0MA00455C","article-title":"Nanoparticle mediated alteration of EMT dynamics: an approach to modulate cancer therapeutics","volume":"1","author":"Sen","year":"2020","journal-title":"Mater. Adv."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0575","doi-asserted-by":"crossref","first-page":"842","DOI":"10.20892\/j.issn.2095-3941.2020.0005","article-title":"Adaptive response of resistant cancer cells to chemotherapy","volume":"17","author":"Chern","year":"2020","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0580","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","article-title":"Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems","volume":"29","author":"Bajracharya","year":"2022","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0585","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.nano.2015.10.018","article-title":"Advances in silica based nanoparticles for targeted cancer therapy","volume":"12","author":"Yang","year":"2016","journal-title":"Nanomedicine"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189261_bb0590","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1039\/c2cs15344k","article-title":"Targeted polymeric therapeutic nanoparticles: design, development and clinical translation","volume":"41","author":"Kamaly","year":"2012","journal-title":"Chem. Soc. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189261_bb0595","first-page":"1","article-title":"An overview of targeted cancer therapy","volume":"5","author":"Padma","year":"2015","journal-title":"BioMedicine (Netherlands)"},{"key":"10.1016\/j.bbcan.2025.189261_bb0600","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.msec.2018.05.011","article-title":"Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL\/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma","volume":"91","author":"Gan","year":"2018","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.bbcan.2025.189261_bb0605","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijbiomac.2017.10.113","article-title":"Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy","volume":"110","author":"Son","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbcan.2025.189261_bb0610","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1039\/c2cs15344k","article-title":"Nanomedicine themed issue targeted polymeric therapeutic nanoparticles: design, development and clinical translationw","volume":"41","author":"Caruso","year":"2012","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189261_bb0615","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189261_bb0620","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/pharmaceutics13091433","article-title":"Peptide-conjugated nano delivery systems for therapy and diagnosis of cancer","volume":"13","author":"Gaurav","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2025.189261_bb0625","first-page":"14","article-title":"Peptide-based delivery of therapeutics in cancer treatment","author":"Samec","year":"2022","journal-title":"Mater. Today Biol."},{"key":"10.1016\/j.bbcan.2025.189261_bb0630","article-title":"Tumor-microenvironment- responsive size-shrinkable drug-delivery nanosystems for deepened penetration into tumors","volume":"27","author":"Cheng","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2025.189261_bb0640","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1089446","article-title":"Hypoxia-responsive nanomaterials for tumor imaging and therapy","volume":"12","author":"Xia","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189261_bb0645","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1039\/C9NR09071A","article-title":"Advanced nanotechnology for hypoxia-associated antitumor therapy","volume":"12","author":"Zhao","year":"2020","journal-title":"Nanoscale [Internet]"},{"key":"10.1016\/j.bbcan.2025.189261_bb0650","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/cells10030541","article-title":"Targeting the hypoxic and acidic tumor microenvironment with ph-sensitive peptides","volume":"10","author":"Dharmaratne","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189261_bb0655","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jconrel.2020.09.055","article-title":"Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment","volume":"329","author":"Sonju","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189261_bb0660","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ejmech.2018.12.035","article-title":"Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment","volume":"163","author":"Zhuang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189261_bb0665","doi-asserted-by":"crossref","first-page":"18462","DOI":"10.1021\/acsami.7b02457","article-title":"PH-sensitive delivery vehicle based on folic acid-conjugated polydopamine-modified mesoporous silica nanoparticles for targeted Cancer therapy","volume":"9","author":"Cheng","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbcan.2025.189261_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.115498","article-title":"Anisamide-functionalized pH-responsive amphiphilic chitosan-based paclitaxel micelles for sigma-1 receptor targeted prostate cancer treatment","volume":"229","author":"Qu","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bbcan.2025.189261_bb0675","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.597634","article-title":"External and internal stimuli-responsive metallic Nanotherapeutics for enhanced anticancer therapy","volume":"7","author":"Mohapatra","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bbcan.2025.189261_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108485","article-title":"Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs","volume":"691","author":"Hashemi","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbcan.2025.189261_bb0685","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.2147\/IJN.S165210","article-title":"Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional\/herbal medicines in cancer therapy: a systematic review","volume":"13","author":"Muhamad","year":"2018","journal-title":"Int. J. Nanomedicine"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189261_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21239123","article-title":"Aptamer-functionalized nanoparticles in targeted delivery and Cancer therapy","volume":"21","author":"Fu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189261_bb0695","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejpb.2016.07.007","article-title":"Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy","volume":"107","author":"Chen","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189261_bb0700","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","author":"Attia","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189261_bb0705","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/jpm11060571","article-title":"Recent advances in tumor targeting via epr effect for cancer treatment","volume":"11","author":"Subhan","year":"2021","journal-title":"J. Person. Med."},{"issue":"38","key":"10.1016\/j.bbcan.2025.189261_bb0710","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189261_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114449","article-title":"Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms","volume":"188","author":"Zi","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-14-41","article-title":"The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance","volume":"14","author":"Kharaishvili","year":"2014","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2025.189261_bb0725","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/cancers10120471","article-title":"Chemoresistance and the self-maintaining tumor microenvironment","volume":"10","author":"Yeldag","year":"2018","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0730","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/acscentsci.9b01139","article-title":"Size-tunable strategies for a tumor targeted drug delivery system","volume":"6","author":"Yu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bbcan.2025.189261_bb0735","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.597634","article-title":"External and internal stimuli-responsive metallic nanotherapeutics for enhanced anticancer therapy","volume":"7","author":"Mohapatra","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189261_bb0740","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","article-title":"Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery","volume":"18","author":"Majumder","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bbcan.2025.189261_bb0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","article-title":"Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review","volume":"15","author":"Hossen","year":"2019","journal-title":"J. Adv. Res."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189261_bb0750","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1039\/C5MD00365B","article-title":"Multi-drug delivery nanocarriers for combination therapy","volume":"6","author":"Gadde","year":"2015","journal-title":"Medchemcomm"},{"issue":"192","key":"10.1016\/j.bbcan.2025.189261_bb0755","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biomaterials.2018.10.036","article-title":"Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer","volume":"1","author":"Lin","year":"2019","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189261_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-019-2669-5","article-title":"Anti-GPC3 antibody tagged cationic switchable lipid-based nanoparticles for the co-delivery of anti-miRNA27a and Sorafenib in liver cancers","volume":"36","author":"Wang","year":"2019","journal-title":"Pharm. Res."},{"issue":"47","key":"10.1016\/j.bbcan.2025.189261_bb0765","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1039\/C7PY01701D","article-title":"Co-delivery of doxorubicin and methotrexate by dendritic chitosan-g-mPEG as a magnetic nanocarrier for multi-drug delivery in combination chemotherapy","volume":"8","author":"Rahimi","year":"2017","journal-title":"Polym. Chem."},{"key":"10.1016\/j.bbcan.2025.189261_bb0775","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.actbio.2018.03.013","article-title":"Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy","volume":"71","author":"Xie","year":"2018","journal-title":"Acta Biomater."},{"issue":"29","key":"10.1016\/j.bbcan.2025.189261_bb0780","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado0082","article-title":"STING activation disrupts tumor vasculature to overcome the EPR limitation and increase drug deposition","volume":"10","author":"Jiang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2025.189261_bb0785","doi-asserted-by":"crossref","unstructured":"Wagner MJ, Mitra R, Mcarthur MJ, Baze W, Barnhart K, Wu SY, et al. Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-Targeted siRNA). Mol. Cancer Ther. 2017 16(6):1114\u201323. Jun 1 [cited 2024 Nov 16]; Available from: \/mct\/article\/16\/6\/1114\/92207\/Preclinical-Mammalian-Safety-Studies-of-EPHARNA.","DOI":"10.1158\/1535-7163.MCT-16-0541"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00781-z","article-title":"Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids","volume":"19","author":"Oner","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbcan.2025.189261_bb0800","article-title":"Nucleus-targeting phototherapy nanodrugs for high-effective anti-cancer treatment","author":"Long","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189261_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112712","article-title":"A novel carbon-nanodots-based theranostic nano-drug delivery system for mitochondria-targeted imaging and glutathione-activated delivering camptothecin","volume":"218","author":"Gong","year":"2022","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0810","first-page":"1","article-title":"Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives","volume":"10","author":"Luobin","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189261_bb0815","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2023.02.023","article-title":"Overcoming drug resistance with a docetaxel and disulfiram loaded pH-sensitive nanoparticle","volume":"356","author":"Swetha","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2025.189261_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122763","article-title":"A cuproptosis-based nanomedicine suppresses triple negative breast cancers by regulating tumor microenvironment and eliminating cancer stem cells","volume":"313","author":"Xiao","year":"2025","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189261_bb0825","doi-asserted-by":"crossref","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for Cancer therapy: current progress and challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.bbcan.2025.189261_bb0830","first-page":"97","article-title":"Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity","volume":"10","author":"Lee","year":"2015","journal-title":"Int. J. Nanomed."},{"issue":"47","key":"10.1016\/j.bbcan.2025.189261_bb0835","doi-asserted-by":"crossref","first-page":"11335","DOI":"10.1039\/D3TB01490H","article-title":"Different drug loading methods and antibiotic structure modulate the efficacy of polydopamine nanoparticles as drug nanocarriers","volume":"11","author":"Patel","year":"2023","journal-title":"J. Mater. Chem. B"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:06:49Z","timestamp":1742296009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":160,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0304419X25000034"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189261","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combating chemoresistance: Current approaches & nanocarrier mediated targeted delivery","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189261"}}